Physician profile

Arun Solanki

Neurology with Special Qualifications in Child Neurology · Germantown, TN

NPI 1821331000

$7,157.67

in general payments reported to CMS, 2019-2025

46 companies · $1,695 in 2025

The $1,695 reported for 2025 was more than what 77% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,389.33
Travel and Lodging$1,380.77

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Biogen, INC. $1,729.30 2021-2025 Skyclarys
Ucb, INC. $586.44 2019-2023 Briviact, Nayzilam
Novartis Pharmaceuticals Corporation $524.45 2020-2023
Ipsen Biopharmaceuticals, INC $418.24 2019-2022
Sk Life Science, INC. $391.91 2020-2023
Supernus Pharmaceuticals, INC. $365.27 2021-2023 Qelbree
Sunovion Pharmaceuticals INC. $262.42 2021-2022
Alexion Pharmaceuticals, INC. $218.79 2019-2023 Soliris
Amgen INC. $216.68 2019-2020
Emd Serono, INC. $174.32 2020-2021
Tris Pharma INC $163.63 2020-2022
Ironshore Pharmaceuticals INC. $158.64 2019-2023 Jornay Pm
Allergan, INC. $129.73 2019-2021
Amneal Pharmaceuticals LLC $122.14 2020-2023 Rytary
Aquestive Therapeutics, INC. $100.38 2020-2021
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Neurocrine Biosciences, INC. $99.63 2022-2023 Ongentys, Ingrezza
Acadia Pharmaceuticals INC $98.07 2020-2021
Livanova USA, INC. $97.49 2020
Kyowa Kirin, INC. $93.76 2020-2021
Jazz Pharmaceuticals INC. $93.61 2022-2023 Epidiolex
Banner Life Sciences, LLC $91.96 2021-2023
Takeda Pharmaceuticals U.S.A., INC. $88.29 2020-2021
Csl Behring $86.68 2019-2020
Corium, LLC $77.96 2022-2023 Azstarys, Adlarity
Genzyme Corporation $68.76 2021
Genentech USA, INC. $63.49 2020-2023 Ocrevus
Argenx US, INC. $59.31 2022-2023 Vyvgart
Neurelis, INC. $53.08 2020-2023 Valtoco
Lilly USA, LLC $51.76 2019-2022
Teva Pharmaceuticals USA, INC. $44.77 2023 Austedo Xr
Nevro Corp. $44.46 2023 Senza
Upsher-Smith Laboratories LLC $41.12 2021
Lundbeck LLC $36.74 2020-2022
Greenwich Biosciences, INC. $36.73 2020
Shire North American Group INC $32.00 2019
Tanabe Pharma America, INC. $31.13 2020
Adamas Pharmaceuticals, INC. $26.73 2019
Harmony Biosciences LLC $25.79 2023 Wakix
Ns Pharma, INC. $24.64 2022
Vanda Pharmaceuticals INC. $23.76 2021
Impel Pharmaceuticals INC. $21.56 2022
Alnylam Pharmaceuticals INC. $20.65 2023 Onpattro
Grt US Holding, INC. $17.35 2021
W. L. Gore & Associates, INC. $15.39 2023 Gore Cardioform Septal Occluder
Avion Pharmaceuticals $14.78 2022
Avanir Pharmaceuticals, INC. $13.88 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Arun Solanki

$7,157.67

in general payments reported 2019-2025

Years
2019-2025
Top company
Biogen, INC.
Context
The $1,695 reported for 2025 was more than what 77% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).

https://glasscript.com/doctor/5705249/arun-solanki

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.